Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice
The switch to faricimab in a T&E regimen significantly increased treatment intervals maintaining BCVA in patients with nAMD under other anti-VEGF treatments. No serious adverse events were reported. Longer follow-up is needed to confirm these results.
Authors
- Mariluz Puertas (ORCID: https://orcid.org/0000-0001-5557-6822)
- Ignacio Flores‐Moreno (ORCID: https://orcid.org/0000-0003-4236-514X)
- Jorge Ruiz‐Medrano (ORCID: https://orcid.org/0000-0002-1105-9265)
- María García‐Zamora (ORCID: https://orcid.org/0000-0003-3716-4992)
- José M. Ruiz‐Moreno (ORCID: https://orcid.org/0000-0001-9636-0788)
- Iulia Pana
Institutions
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Instituto de Microcirugía Ocular (ES)
- University of Castilla-La Mancha (ES)
Publication Details
- Journal
- International Journal of Retina and Vitreous
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1186/s40942-025-00776-0
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00